High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies.
A Phase II Study of High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies at Initial Diagnosis.
Sponsor: Keimyung University Dongsan Medical Center
Listed as NCT01730651, this NA trial focuses on Cervical Cancer and remains ongoing. Sponsored by Keimyung University Dongsan Medical Center, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting NA
▶ Show 5 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Sep 2019 — Oct 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2019 [monthly]
Recruiting NA
-
Oct 2017 — Jun 2018 [monthly]
Recruiting NA
Phase: PHASE2 → NA
-
Jan 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Keimyung University Dongsan Medical Center
- National Cancer Center, Korea
For direct contact, visit the study record on ClinicalTrials.gov .